ATR and neoplasm: Enrolled patients had germline pathogenic or likely pathogenic mutations in ATM (n = 3), BRIP1 (n = 2), CHEK2 (n = 3), FANCA (n = 1) and PALB2 (n = 6) or somatic mutations in ATM (n = 2), ATR (n = 1), PTEN (n = 5) and RAD50 (n = 1) as detected by any CLIA-approved NGS assay performed on either germline tissue or tumor tissue (Table 1).